Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 17;13(1):58.
doi: 10.1186/s13741-024-00418-3.

Hemostatic effects of tranexamic acid in cardiac surgical patients with antiplatelet therapy: a systematic review and meta-analysis

Lijuan Tian  1 , Xiaotao Li  2 , Lixian He  2 , Hongwen Ji  1 , Yuntai Yao  3 ; Evidence in Cardiovascular Anesthesia (EICA) Group
Affiliations
Review

Hemostatic effects of tranexamic acid in cardiac surgical patients with antiplatelet therapy: a systematic review and meta-analysis

Lijuan Tian et al. Perioper Med (Lond). .

Abstract

Background: The purpose of the current study was to assess the efficacy of tranexamic acid (TXA) on reducing bleeding in cardiac surgical patients with preoperative antiplatelet therapy (APT).

Methods: Five electronic databases were searched systematically for randomized-controlled trials (RCTs) assessing the impact of intravenous TXA on post-operative bleeding on cardiac surgical patients with preoperative APT until May 2024. Primary outcome of interest was post-operative blood loss. Secondary outcomes of interest included the incidence of reoperation due to post-operative bleeding, post-operative transfusion requirements of red blood cells (RBC), fresh-frozen plasma (FFP), and platelet concentrates. Mean difference (MD) with 95% confidence interval (CI) or odds ratios (OR) with 95% CI was employed to analyze the data. Subgroup and meta-regression analyses were performed to assess the possible influence of TXA administration on reducing bleeding and transfusion requirements.

Results: A total of 12 RCTs with 3018 adult cardiac surgical patients (TXA group, 1510 patients; Control group, 1508 patients) were included. The current study demonstrated that TXA significantly reduced post-operative blood loss (MD = - 0.38 L, 95% CI: - 0.73 to - 0.03, P = 0.03; MD = - 0.26 L, 95% CI: - 0.28 to - 0.24, P < 0.00001; MD = - 0.37 L, 95% CI: - 0.63 to - 0.10, P = 0.007) in patients receiving dual antiplatelet therapy (DAPT), aspirin, or clopidogrel, respectively. Patients in TXA group had significantly lower incidence of reoperation for bleeding as compared to those in Control group. The post-operative transfusion of RBC and FFP requirements was significantly lower in TXA group than Control group. Subgroup analyses showed that studies with DAPT discontinued on the day of surgery significantly increased the risk of post-operative blood loss [(MD: - 1.23 L; 95% CI: - 1.42 to - 1.04) vs. (MD: - 0.16 L; 95% CI: - 0.27 to - 0.05); P < 0.00001 for subgroup difference] and RBC transfusion [(MD: - 3.90 units; 95% CI: - 4.75 to - 3.05) vs. (MD: - 1.03 units; 95% CI: - 1.96 to - 0.10); P < 0.00001 for subgroup difference] than those with DAPT discontinued less than 5-7 days preoperatively.

Conclusions: This meta-analysis demonstrated that TXA significantly reduced post-operative blood loss and transfusion requirements for cardiac surgical patients with preoperative APT. These potential clinical benefits may be greater in patients with aspirin and clopidogrel continued closer to the day of surgery.

Trial registration number: CRD42022309427.

Keywords: Antiplatelet therapy; Cardiac surgery; Post-operative bleeding; Tranexamic acid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of the study search and selection process
Fig. 2
Fig. 2
Forest plot of A post-operative bleeding volume and B the incidence of reoperation for bleeding
Fig. 3
Fig. 3
Forest plot of A RBC transfusion volume and B transfusion rate
Fig. 4
Fig. 4
Forest plot of A FFP transfusion volume and B transfusion rate
See this image and copyright information in PMC

References

    1. Ahn SW, Shim JK, Youn YN, Song JW, Yang SY, Chung SC, et al. Effect of tranexamic acid on transfusion requirement in dual antiplatelet-treated anemic patients undergoing off-pump coronary artery bypass graft surgery. Circ J. 2012;76(1):96–101. doi: 10.1253/circj.CJ-11-0811. - DOI - PubMed
    1. Altun G, Hemşinli D, Pulathan Z, Civelek A. Emergency coronary bypass surgery in patients under the influence of dual antiplatelet therapy: effects of tranexamic acid and desmopressin acetate. Turk J Med Sci. 2017;47(6):1708–1714. doi: 10.3906/sag-1612-140. - DOI - PubMed
    1. Amour J, Garnier M, Szymezak J, Le Manach Y, Helley D, Bertil S, et al. Prospective observational study of the effect of dual antiplatelet therapy with tranexamic acid treatment on platelet function and bleeding after cardiac surgery. Br J Anaesth. 2016;117(6):749–757. doi: 10.1093/bja/aew357. - DOI - PubMed
    1. Andersson L, Nilsoon IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci. 1968;146(2):642–658. doi: 10.1111/j.1749-6632.1968.tb20322.x. - DOI - PubMed
    1. Banihashem N, Khorasani M, Vaffai H, Naziri F, Khafri S, Seyfi S. The effect of low- dose tranexamic acid on postoperative blood loss in patients treated with clopidogrel and aspirin. Caspian J Intern Med. 2019;10(2):156–161. - PMC - PubMed

LinkOut - more resources